Tag: Surmodics

Surmodics Reports First Quarter Fiscal 2022 Results

EDEN PRAIRIE, Minn.–(BUSINESS WIRE)–Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced results for its fiscal 2022 first quarter ended December 31, 2021. Summary of First Quarter and Recent Highlights Revenue of $23.0 million, an increase of 3% year-over-year GAAP EPS of $(0.20), […]

Surmodics Reports Fourth Quarter Fiscal 2021 Results and Issues Fiscal 2022 Revenue and EPS Guidance

EDEN PRAIRIE, Minn.–(BUSINESS WIRE)–Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced results for its fiscal 2021 fourth quarter ended September 30, 2021 and provided its financial outlook for its fiscal 2022. Summary of Fourth Quarter and Recent Highlights Revenue of $24.0 million, […]

Surmodics Announces Successful First Patient Uses of Sublime™ Radial Access .018 RX PTA Dilatation Catheter

Latest addition to the Sublime™ Radial Access Platform expands market opportunity by increasing size offering to treat larger vessels and providing the shaft length needed to treat more distal lesions using a radial approach EDEN PRAIRIE, Minn.–(BUSINESS WIRE)–Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care […]

Surmodics Announces Successful First Patient Use of Pounce™ Thrombectomy System

Standalone arterial mechanical thrombectomy device removes 30 cm of subacute thrombus in first clinical case EDEN PRAIRIE, Minn.–(BUSINESS WIRE)–Surmodics, Inc. (NASDAQ: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced that J. Michael Bacharach, MD, vascular interventionalist/cardiologist at North Central Heart, a division of Avera […]

Surmodics Builds Thrombectomy Portfolio with Acquisition of Vetex Medical Limited

Deal adds second FDA 510(k) cleared device to thrombectomy platform Easy-to-use, stand-alone, single session mechanical thrombectomy for removal of venous clot in highly attractive, rapidly growing and significantly under-penetrated market FDA 510(k) cleared (Dec. 2020) and CE Mark Certification (May 2021) 12-month follow-up data of 19-patient feasibility trial presented at American Venous Forum (March 2021) […]

Surmodics Announces Successful First Patient Uses of Two Sublime™ Radial Access Platform Devices

Sublime™ Radial Access .014 RX PTA Dilatation Catheter, Sublime Radial Access Guide Sheath Deliver Outstanding Performance in Initial Physician Evaluations EDEN PRAIRIE, Minn.–(BUSINESS WIRE)–Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced the successful first uses with patients for two devices within its Sublime™ […]

Surmodics Reports First Quarter Fiscal 2021 Results

EDEN PRAIRIE, Minn.–(BUSINESS WIRE)–Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced results for its fiscal 2021 first quarter ended December 31, 2020. Summary of First Quarter and Recent Highlights Revenue of $22.3 million, a decrease of 1% year-over-year GAAP EPS of ($0.02), […]

12-Month Data from Surmodics’ TRANSCEND Trial Presented at LINC 2021 Event

SurVeil™ Drug Coated Balloon (DCB) demonstrates non-inferior safety and efficacy, while using a substantially lower drug dose, vs. the IN.PACT® Admiral® DCB for treatment of femoropopliteal lesions. EDEN PRAIRIE, Minn.–(BUSINESS WIRE)–Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced that 12-month data from its TRANSCEND […]

6-Month Data From the Surmodics Avess™ AV Fistula DCB First-in-Human Study Presented at VIVA 2020

Study finds 100 percent target lesion patency at 30 days; 90.9 percent of patients free from revascularization at 6 months EDEN PRAIRIE, Minn.–(BUSINESS WIRE)–Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced that 6-month data from the AVESS first-in-human (FIH) study of the […]

Surmodics Receives FDA 510(k) Clearance for Pounce™ Thrombus Retrieval System

Next-generation technology provides easy, effective clot removal from peripheral arterial vasculature EDEN PRAIRIE, Minn.–(BUSINESS WIRE)–Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its Pounce™ Thrombus Retrieval System. The Pounce Thrombus Retrieval System […]